Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Novo Nordisk's total addressable market for GLP-1 drugs could grow significantly if this happens. The official WHO report that will include those recommendations is due out in August. The stock is ...

--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Doha, Qatar: Ebn Sina Medical, a subsidiary of Aamal Company QPSC and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish leading global healthcare company renowned for its ...

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of Hims & Hers Health, LifeMD, and Ro to drive direct-to-consumer sales of ...

Unfortunately for Novo Nordisk investors, shares of the Danish pharmaceutical have dived by 36% across that stretch of time. We can't only blame Lilly for this. Given the massive demand for ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...